Arrowhead Pharmaceuticals (ARWR) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Arrowhead Pharmaceuticals (ARWR) over the past year, gaining 304.8% versus a gain of 74.0%. Over five years, ARWR leads with a -5.2% price change compared with -58.1% for SYRE. Arrowhead Pharmaceuticals is the larger company by market cap ($8.86 billion vs $7.91 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | SYRE |
|---|---|---|
| Share price | $62.75 | $85.69 |
| Market cap | $8.86B | $7.91B |
| 1-day change | +3.31% | +7.25% |
| YTD return | -5.48% | +161.57% |
| 1-year return | +74.02% | +304.77% |
| 5-year return | -5.15% | -58.10% |
| EPS (TTM) | $-2.28 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $829.45M | $0 |
| Revenue growth (YoY) | +23258.15% | — |
| Net income (latest FY) | $-1.63M | $-155.20M |
| Operating margin | 11.86% | — |
| Net margin | -0.20% | — |
| 52-week high | $95.49 | $110.18 |
| 52-week low | $34.61 | $18.12 |
| Distance from 52-week high | -34.29% | -22.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +70.88% | +40.28% |
| Average volume | 1.89M | 1.22M |
| Shares outstanding | 141.25M | 92.29M |
| Employees | 711 | 125 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed ARWR by 230.8 percentage points over the past year.
- The two companies sit in different sectors: Arrowhead Pharmaceuticals in Health Care and Spyre Therapeutics in Healthcare.
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 711 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Healthcare · Biotechnology · 125 employees
ARWR vs SYRE FAQ
Which is bigger, Arrowhead Pharmaceuticals or Spyre Therapeutics?
Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $8.86B compared with $7.91B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, ARWR or SYRE?
SYRE returned +304.77% over the past 12 months, compared with +74.02% for ARWR (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Spyre Therapeutics in the same industry?
No. Arrowhead Pharmaceuticals is in the Health Care sector, while Spyre Therapeutics is in Healthcare.